Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
Open Access
- 19 June 2021
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 22 (1) , 65-74
Abstract
Background & Aims: A plethora of second-line therapies have been recently introduced for hepatocellular carcinoma (HCC) treatment with promising results. A meta-analysis of second-line treatments for HCC has been performed to better tailor their use based on improved patient stratification and to identify the best available option. Methods: Pubmed, Scopus, Web of Science, and ClinicalTrials.gov were searched for randomized controlled trials evaluating second-line treatment for advanced HCC in patients already treated with sorafenib. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS) and drug withdrawal due to adverse events. Network meta-analyses were performed considering placebo as the basis for comparison in efficacy and safety analyses. Subgroup stratification considered gender, age, sorafenib-responsiveness and drug tolerability, viral infection, macrovascular invasion, HCC extrahepatic spread, performance status, and alpha-fetoprotein levels. Results: Fourteen phase II or III randomized controlled trials, involving 5,488 patients and 12 regimens, were included in the analysis. Regorafenib (hazard ratio (HR) = 0.63, 95% confidence interval (CI) = 0.50–0.79), cabozantinib (HR = 0.76, 95% CI = 0.63–0.92), and ramucirumab (HR = 0.82, 95% CI = 0.70–0.76) significantly prolonged OS compared with placebo. Cabozantinib (HR = 0.44, 95% CI = 0.36–0.52), regorafenib (HR = 0.46, 95% CI = 0.37–0.56), ramucirumab (HR = 0.54, 95% CI = 0.43–0.68), brivanib (HR = 0.56, 95% CI = 0.42–0.76), S-1 (HR = 0.60, 95% CI = 0.46–0.77), axitinib (HR = 0.62, 95% CI = 0.44–0.87), and pembrolizumab (HR = 0.72, 95% CI = 0.57–0.90) significantly improved PFS compared with placebo. None of the compared drugs deemed undoubtedly superior after having performed a patients’ stratification. Conclusions: The results of this network meta-analysis suggest the use of regorafenib and cabozantinib as second-line treatments in HCC.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (20441)
- Regione Puglia
- Universita degli Studi di Bari Aldo Moro
This publication has 35 references indexed in Scilit:
- Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaJournal of Hepatology, 2016
- Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinomaAnnals of Oncology, 2015
- Ranking treatments in frequentist network meta-analysis works without resampling methodsBMC Medical Research Methodology, 2015
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2015
- Treatment Algorithms for Managing Hepatocellular CarcinomaJournal of Clinical and Experimental Hepatology, 2014
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibJAMA, 2014
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJournal of Clinical Oncology, 2013
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyThe Lancet Oncology, 2013
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999